Viking Therapeutics, Inc (VKTX) Financials
Key financial figures for Viking Therapeutics, Inc (Q3 2026).
Viking Q3 2026 net loss widened to $183.2 million ($1.55 per share) as Phase 3 spending ramped, with $960 million of cash and short-term investments after the September financing. Viking is pre-revenue: revenues were nil in the quarter and the year-ago quarter. Research and development expense was $166.8 million, up from $90.0 million a year earlier, on clinical studies, manufacturing for its drug candidates, stock-based compensation, salaries and third-party consultants. General and administrative expense was $20.3 million versus $8.6 million a year earlier, driven by legal and patent services, consultants, stock-based compensation and salaries. Loss from operations was $187.1 million versus $98.6 million. On the outlook: The release gives no financial guidance. Timing statements: VANQUISH-1 and VANQUISH-2 expected to complete in 2027; VANQUISH extension studies to start in 1Q27 with results in 2028; Part 2 maintenance study results expected in 2027; Phase 1 SAD study of VK3019 to complete in the fourth quarter of 2026, with a multiple ascending dose study starting 1Q27. Figures are for Q3 2026, as Viking Therapeutics, Inc. reported them.
- Revenue
- $0
- Net Income
- -$183M
- EPS
- $-1.55
- Total Assets
- $977M
- Operating Cash Flow
- -$138M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$183M | -$1.55 | -$138M | |
| Q2 FY2026 | $0 | -$128M | -$1.10 | -$125M | |
| Q1 FY2026 | $0 | -$158M | -$1.37 | -$114M | |
| Q4 FY2025 | $0 | -$158M | -$1.38 | -$85M | |
| Q3 FY2025 | $0 | -$91M | -$0.81 | -$94M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$360M | -$3.19 | -$279M | |
| FY2024 | $0 | -$110M | -$1.01 | -$88M | |
| FY2023 | $0 | -$86M | -$0.91 | -$73M |
Frequently asked questions
What was Viking Therapeutics, Inc.'s revenue last quarter?
Viking Therapeutics, Inc. reported revenue of $0.00 for Q3 FY2026.
Is Viking Therapeutics, Inc. profitable?
Not in its most recent reported period. Viking Therapeutics, Inc. reported a net loss of $183.2 million for Q3 FY2026.
How much free cash flow did Viking Therapeutics, Inc. generate?
Viking Therapeutics, Inc. generated free cash flow of -$138.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Viking Therapeutics, Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.